Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

External-applied medicine for treating terminal neuritis and preparation thereof

A technology for peripheral neuritis and external medicine, applied in the field of Chinese and Mongolian medicine, can solve problems such as many side effects and no treatment method, achieve significant curative effect, and improve limb microcirculation disorders and neuropathic states.

Active Publication Date: 2005-10-12
YUANHE PHARMA CO LTD
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there are many studies on the disease at home and abroad, but there is no good treatment method. Most of the domestic neurotrophic drugs, such as vitamin B complex and vasodilators, are used for treatment, while foreign countries use inositol and aldose reductase in recent years. Inhibitors, etc., although they have certain curative effects, they also have many side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0047] Experimental Example 1: Pharmacodynamic study of Gaza Luoshu Gel, an external drug for treating peripheral neuritis

[0048] External application of the drug can significantly improve the heat radiation pain threshold of rats, and the pain threshold after high, medium and low doses of drug application for 20 minutes is 68.3%, 44.8% and 37.9% higher than that of the control group, and the effect can last for more than 60 minutes. The analgesic effect of the hot plate on mice was increased by 24.6%, 29.3%, and 16.7% compared with the pain threshold of the control group. The effect can last for more than 50 minutes. High, medium, and low doses of xylene inhibited inflammation in mice by 19.0%, 20.3%, and 7.7%, respectively. For carrageenan inflammation in rats, high and middle doses showed significant inhibitory effects, and low doses showed a tendency to inhibit. It can significantly increase the number of open capillaries in the ear shell of mice, and accelerate the bl...

experiment example 2

[0069] Experimental Example 2: Long-term Toxicity Test and Documentation in Rats

[0070] Rats used in the test were divided into control group, high dose group, middle dose group and low dose group, and the application areas were 10%, 6%, and 2%, respectively. The drug was applied continuously for 24 weeks, and the recovery after drug withdrawal was observed for 2 weeks. . The results showed that there were no obvious changes in rats' physical signs, blood analysis, organ index, liver and kidney functions and tissue sections.

[0071] Objective To observe whether long-term drug administration produces toxic side effects in rats, provide target organs of toxic reactions and the reversible degree of damage, determine the dose of toxic reactions, and provide reference for formulating safe doses for human use.

[0072] 1. Materials

[0073] Animals 80 Wistar rats, weighing 58g-76g, aged 4-5 weeks, half male and half male, were provided by the Experimental Animal Center of Inner...

Embodiment 1

[0105] The preparation of pharmaceutical gel of the present invention

[0106] (a): take by weighing 120g of each raw material Aconitum Aconitum, 240g of Rhizoma Chuanxiong and 25g of Radix Notoginseng, set aside;

[0107] (b): 120g of Aconitum Aconitum is crushed into a coarse powder and percolated with 6 times the amount of 50% ethanol, and the percolate is collected;

[0108] (c): 240g of Rhizoma Chuanxiong and 25g of Panax notoginseng were crushed into coarse powder, percolated with 6 times the amount of 50% ethanol, and the percolation liquid was collected;

[0109] (d): Combine (b), (c) percolate, reclaim ethanol to thick paste, add triethanolamine 5g, propylene glycol 50g, Tween-80 10g, stir evenly;

[0110] (e): Add the mixture of (d) into 20 g of carbomer solution with a concentration of 1% to 3%, fully stir and grind to obtain the finished gel.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An exterior-applied Chinese medicine in the form of gel for treating peripheral neurtitis is prepared from aconite root, Chuan-xiong rhizome and notoginseng. Its advantages are high curative effect, and no pollution to clothes.

Description

Technical field: [0001] The invention relates to an external medicine for treating peripheral neuritis and a preparation method thereof, belonging to the field of Chinese and Mongolian medicines. Background technique: [0002] Diabetes, rheumatism, malnutrition, etc. are the main symptoms of peripheral neuritis, especially the peripheral neuritis caused by diabetes accounts for the majority. Diabetic peripheral neuropathy is one of the three major complications of diabetes, and it is also one of the difficult topics in the field of diabetes research. With the continuous development of my country's economy and related lifestyle changes, the prevalence of diabetes is increasing at an alarming rate . According to statistics, the current incidence of diabetes in my country is 3.2%, and it is estimated that there are about 30 million patients in the country. Among them, the incidence of diabetic peripheral neuritis is 50% to 85% when the age is over 40 years old, and the incidenc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61P25/02
Inventor 邬林祥温爱平
Owner YUANHE PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com